We are live on
!
Find out more
AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$790M
1-Year Est. Return
223.66%
This Fund
S&P 500
This Quarter
Est. Return
+52.92%
1 Year Est. Return
+223.66%
3 Year Est. Return
+485.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$662M
AUM Growth
+$141M
(+27%)
Cap. Flow
-$4.74M
Cap. Flow
% of AUM
-0.72%
Top 10 Holdings %
Top 10 Hldgs %
99.6%
Holding
13
New
–
Increased
–
Reduced
–
Closed
2
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JBIO
Jade Biosciences
JBIO
|
+$4.52M |
| 2 |
Spero Therapeutics
SPRO
|
+$220K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
AWG
AT
MTWSIF
VH
M
AI
VCM
SWIG
Atlas Venture Life Science Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Atlas Venture Life Science Advisors held 13 positions worth $662M, up 27% from $522M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Atlas Venture Life Science Advisors's Q2 2025 filing shows 2 closed positions. The largest sale was Jade Biosciences, an estimated $4.52M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Atlas Venture Life Science Advisors fully exited Jade Biosciences in Q2 2025, selling an estimated $4.52M.
- Atlas Venture Life Science Advisors's ten largest holdings make up 100% of its $662M portfolio in Q2 2025.
- Atlas Venture Life Science Advisors opened 0 new positions and closed 2 in Q2 2025.
- Atlas Venture Life Science Advisors's portfolio value rose 27% quarter-over-quarter to $662M.
Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.